Collegium Pharmaceutical financials
$22.23−1.77%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $780.6M | $631.4M | $566.8M | $463.9M | $276.9M | $310.0M | $296.7M | $280.4M | $28.5M | $1.7M |
| Gross profit | $463.3M | $377.3M | $326.2M | $209.5M | $150.6M | $240.5M | $103.0M | $114.7M | $25.9M | $1.5M |
| Gross margin | 59.3% | 59.8% | 57.5% | 45.2% | 54.4% | 77.6% | 34.7% | 40.9% | 90.9% | 87.6% |
| Operating income | $179.6M | $169.9M | $167.0M | $33.3M | $17.6M | $56.2M | -$23.7M | -$20.7M | -$75.4M | -$94.1M |
| Net income | $62.9M | $69.2M | $48.2M | -$25.0M | $71.5M | $26.8M | -$22.7M | -$39.1M | -$74.9M | -$94.2M |
| Net margin | 8.1% | 11.0% | 8.5% | −5.4% | 25.8% | 8.6% | −7.7% | −14.0% | −262.9% | −5504.1% |
| Diluted EPS | $1.73 | $1.86 | $1.29 | $-0.74 | $1.86 | $0.76 | $-0.68 | $-1.19 | $-2.47 | $-3.88 |
| EBITDA | $405.7M | $339.1M | $316.2M | $172.3M | $91.1M | $117.8M | -$8.3M | $90.2M | -$74.9M | -$93.5M |
| Operating cash flow | $329.3M | $205.0M | $274.7M | $124.2M | $103.6M | $93.9M | $27.8M | $169.4M | -$67.0M | -$75.1M |
| Free cash flow | $327.6M | $203.3M | $274.3M | $122.6M | $101.6M | $88.4M | $21.3M | $163.9M | -$68.0M | -$75.5M |
| Diluted shares | 39.7M | 40.4M | 41.8M | 33.8M | 41.0M | 35.2M | 33.5M | 33.0M | 30.3M | 24.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $231.3M | $70.6M | $238.9M | $173.7M | $186.4M | $174.1M |
| Short-term investments | $155.4M | $92.2M | $71.6M | $0.00 | — | — |
| Total debt | $809.3M | $852.5M | $667.2M | $931.4M | $250.0M | $257.1M |
| Total assets | $1.66B | $1.66B | $1.14B | $1.17B | $692.1M | $643.8M |
| Total liabilities | $1.36B | $1.43B | $947.9M | $979.3M | $489.1M | $457.8M |
| Shareholders' equity | $301.7M | $228.8M | $195.4M | $194.8M | $202.9M | $186.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology